Ursodeoxycholic acid for terbinafine-induced toxic hepatitis [4]

Annals of Pharmacotherapy

Volumn 38, Issue 6, 2004, Pages 1088-1089

  Agca, Erhan ^a   Akcay, Ali ^a   Simsek, Halis ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; LIVER ENZYME; STEROID; TERBINAFINE; URSODEOXYCHOLIC ACID;

ADULT; ANAMNESIS; CASE REPORT; CELL PROTECTION; CHOLESTASIS; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TOXICITY; MONOTHERAPY; ONYCHOMYCOSIS; PRIORITY JOURNAL; PRURITUS; TOXIC HEPATITIS; ULTRASOUND;

EID: 2442680778     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D420     Document Type: Letter

References (6)

1. Gupta AK, del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol 1998;23:64-7.
2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
3. Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC. Terbinafine-induced cholestatic liver disease. J Hepatol 1996;24:753-6.
4. Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998;93:459-60.
5. Ajit C, Suvannasankha A, Zaeri N, Muñoz SJ. Terbinafine-associated hepatotoxicity. Am J Med Sci 2003;325:292-5.
6. Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993;104:1736-44.